This activity is expired and is no longer available for CME credit.


Sustained Release Steroid Therapy for Diabetic Macular Edema

Author(s)/Faculty: David G. Dodwell, MD; Michael A. Singer, MD
Release Date: 11/24/2014Expiration Date: 11/23/2015
Credit Type: CMENumber of Credits: 0
Content Type: MonographProvider:
Intravitreal pharmacotherapy, including long-acting corticosteroids, anti-vascular endothelial growth factor (anti-VEGF) agents, and other novel biologics, has spawned new clinical interventions that halt vision loss and in many cases restore useful vision. Adoption of these agents, especially the anti-VEGF medications, has dramatically reduced rates of blindness. In this issue of INTRAVITREAL INTERVENTIONS, retina experts explain the clinically relevant pharmacology behind these agents and detail treatment considerations with use of anti-VEGF injections for patients with wet AMD. This issue also explores the use of surgically implanted intravitreal depot steroid devices for treatment of macular edema due to retinal vein occlusions and for posterior noninfectious uveitis.